title: Efficacy of ustekinumab after failure of infliximab CT-P13 in a HLA-Cw6-positive patient affected by pityriasis rubra pilaris: monitoring with reflectance confocal microscopy (RCM) and optical coherence tomography (OCT).
authors.affiliation: Department of Dermatology, University of Modena and Reggio Emilia, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Paganelli
authors.affiliation: Department of Dermatology, University of Modena and Reggio Emilia, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Ciardo
authors.affiliation: Department of Dermatology, University of Modena and Reggio Emilia, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Odorici
authors.affiliation: Department of Dermatology, University of Modena and Reggio Emilia, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Pellacani
authors.affiliation: Department of Dermatology, University of Modena and Reggio Emilia, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Conti
mesh_terms: D000368:Aged; D003879:Dermatologic Agents / Q000627:therapeutic use; D005260:Female; D015236:HLA-C Antigens / Q000276:immunology*; D006801:Humans; D000069285:Infliximab / Q000494:pharmacology*; D018613:Microscopy, Confocal / Q000379:methods*; D010916:Pityriasis Rubra Pilaris / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012867:Skin / Q000473:pathology*; D041623:Tomography, Optical Coherence / Q000379:methods*; D017211:Treatment Failure; D000069549:Ustekinumab / Q000627:therapeutic use*
chemical_list: D003879:Dermatologic Agents; D015236:HLA-C Antigens; C528994:HLA-C*06 antigen; D000069285:Infliximab; D000069549:Ustekinumab